Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesResverlogix Corp.

Resverlogix Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.08 CAD 0.01 ( 6.67%)
Last update at 2026-11-04T18:12:00Z
VOLUME
64011
Market Cap
33.20M

Momentum Score

…

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.07
Low
0.08
High
52 Week Price Range
0.04
Low
0.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Resverlogix Corp is a clinical-stage biopharma developing apabetalone, a BET inhibitor aimed at modulating lipid and inflammatory pathways in cardiovascular and related diseases. Long-term growth may depend on positive late-stage clinical evidence in targeted high-risk populations, regulatory approvals and commercial partnerships. Investors may view the company as attractive because the mechanism could address residual cardiovascular risk in patients with unmet needs such as chronic kidney disease.
Key risks are dependence on one clinical asset, high clinical and regulatory failure risk, limited cash requiring financing, and competitive pressure.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.07
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.82
ROE
-
Net Debt
72.66M
ROCE
14.44%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Income before tax -7.94M -7.62M -16.73M -3.59M -3.59M
Net income -7.90M -7.63M -16.74M -3.61M -3.61M
Selling general administrative - 1.79M 2.77M 6.94M 6.94M
Gross profit -0.44M -0.48M - - -
Reconciled depreciation - 0.35M 0.72M 1.01M 1.01M
Ebit -5.20M -4.60M - -12.75M -12.75M
Ebitda -4.77M -4.25M - -11.74M -11.74M
Depreciation and amortization 0.44M 0.35M - 1.01M 1.01M
Operating income -5.20M -6.37M -6.21M -12.75M -12.75M
Other operating expenses 5.20M 4.65M - 12.71M 12.71M
Interest expense 4.33M 4.20M 1.83M 1.63M 1.63M
Tax provision - 0.01M 0.01M 0.02M 0.02M
Interest income - 2.65M - 9.15M 9.15M
Net interest income - -3.07M -1.84M -1.67M -1.67M
Income tax expense -0.04M 0.01M - 0.02M 0.02M
Total revenue - 0.00M 0.00M 0.00M 0.00M
Total operating expenses 4.77M 4.65M 6.21M 12.71M 12.71M
Cost of revenue 0.44M 0.48M - - -
Total other income expense net -2.74M -2.97M -8.68M 9.16M 9.16M
Net income from continuing ops - -7.63M -16.74M -3.61M -3.61M
Net income applicable to common shares - -7.63M - -3.61M -3.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Total assets 7.93M 7.34M 6.52M 8.12M 8.12M
Intangible assets 2.58M 2.49M 2.36M 2.21M 2.21M
Other current assets 0.15M 0.04M 0.01M 0.01M 0.01M
Total liab 96.73M 89.08M 80.99M 67.40M 67.40M
Total stockholder equity -88.80M -81.73M -74.47M -59.28M -59.28M
Other current liab 23.22M 0.19M 0.58M 2.15M 2.15M
Common stock 334.32M - - 331.42M 331.42M
Capital stock - 334.62M 333.72M 331.42M 331.42M
Retained earnings -476.96M -470.06M -462.43M -445.69M -445.69M
Other assets - - - 2.60M 2.60M
Cash 0.11M 0.10M 0.01M 0.04M 0.04M
Total current liabilities 43.98M 26.31M 26.86M 22.73M 22.73M
Net debt 72.66M 16.33M 6.70M 6.45M 6.45M
Short term debt 20.76M - - 6.49M 6.49M
Short long term debt - 8.30M 6.71M 6.05M 6.05M
Short long term debt total 72.77M - - 6.49M 6.49M
Other stockholder equity 53.84M - - 54.98M 54.98M
Property plant equipment - - - 0.43M 0.43M
Total current assets 1.60M 1.54M 0.52M 2.89M 2.89M
Net receivables 0.91M - - 0.32M 0.32M
Long term debt - 8.13M - - -
Inventory 0.43M 1.00M 0.30M 2.37M 2.37M
Accounts payable - 16.00M 14.53M 14.10M 14.10M
Non currrent assets other 3.74M 3.32M 3.64M 2.60M 2.60M
Non current assets total 6.33M 5.81M 6.00M 5.23M 5.23M
Capital lease obligations - 0.04M 0.04M 0.44M 0.44M
Long term debt total - - - 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Investments - -0.38M -0.52M -0.47M -0.47M
Change to liabilities - - - -0.10M -0.10M
Total cashflows from investing activities -0.66M -0.38M - -0.47M -0.47M
Net borrowings - 4.38M - -0.55M -0.55M
Total cash from financing activities 4.39M 4.36M 3.09M 4.06M 4.06M
Net income -7.90M -7.63M -16.74M -3.61M -3.61M
Change in cash 0.00M 0.09M -0.04M 0.03M 0.03M
Begin period cash flow 0.10M 0.01M 0.04M 0.01M 0.01M
End period cash flow 0.11M 0.10M 0.01M 0.04M 0.04M
Total cash from operating activities -3.73M -3.89M -2.61M -3.54M -3.54M
Issuance of capital stock - 0.00M 0.28M 4.61M 4.61M
Depreciation 0.44M 0.35M 0.72M 1.01M 1.01M
Other cashflows from investing activities 0.05M 0.10M - -0.02M -0.02M
Dividends paid - 0.00M - - -
Change to inventory 0.14M -0.38M 0.00M -0.01M -0.01M
Change to account receivables -0.68M - - - -
Sale purchase of stock - - - 4.70M 4.70M
Other cashflows from financing activities - -1.64M - 0.45M 0.45M
Capital expenditures 0.01M 0.47M 0.45M 0.45M 0.45M
Change in working capital 0.40M -0.57M 0.61M 4.74M 4.74M
Stock based compensation - 0.30M 1.25M 2.39M 2.39M
Other non cash items 3.34M 3.65M 1.57M -8.08M -8.08M
Free cash flow -3.73M -4.36M -3.06M -3.99M -3.99M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RVX
Resverlogix Corp.		 0.01
6.67%		 0.08 - - 1275.46 47.93 1440.16 -2.80
EPRX
Eupraxia Pharmaceuticals Inc		 0.03
0.31%		 9.68 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1

403 254 9252

https://www.resverlogix.com

Name Title Year Born
Mr. Donald J. McCaffrey Co-Founder, Chairman, Pres, CEO & Sec. NA
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV Chief Financial Officer NA
Dr. Ewelina Kulikowski Ph.D. Chief Scientific Officer NA
Dr. Jan O. Johansson M.D., Ph.D. Sr. VP of Medical Affairs NA
Dr. Michael Sweeney M.D. Sr. VP of Clinical Devel. 1961
Sarah Zapotichny Director of Investor Relations & Corp. Communications NA
Mr. Aaron Bradley Cann C.A., CPA, CBV Chief Financial Officer NA
Dr. Michael Sweeney M.D. Senior Vice President of Clinical Development 1961
Mr. Donald J. McCaffrey Co-Founder, Chairman, President, CEO & Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…